Status:
WITHDRAWN
Cell Therapy as Treatment for Cerebral Palsy
Lead Sponsor:
Neurogen Brain and Spine Institute
Conditions:
Cerebral Palsy
Eligibility:
All Genders
6-35 years
Phase:
PHASE1
Brief Summary
The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.
Eligibility Criteria
Inclusion
- diagnosed cases of any type of Cerebral Palsy
- age above 6 months.
Exclusion
- presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/ Hepatitis C Virus
- malignancies
- bleeding tendencies
- pneumonia
- renal failure
- severe liver dysfunction
- severe anemia \[Hemoglobin \< 8\]
- any bone marrow disorder
- space occupying lesion in brain
- other acute medical conditions such as respiratory infection and pyrexia.
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02241395
Start Date
August 1 2013
End Date
December 1 2018
Last Update
October 25 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurogen brain and spine institute
Navi Mumbai, Maharashtra, India, 400706